主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Wu Yonghui Yan Yan Nie Shaoping
单位:首都医科大学附属北京安贞医院心内冠心病中心,北京100029
英文单位:Intracardiac Coronary Heart Disease Center Beijing Anzhen Hospital Capital Medical University Beijing 100029 China
关键词:急性冠状动脉综合征;高出血风险;经皮冠状动脉介入;预后
英文关键词:Acutecoronarysyndrome;Highbleedingrisk;Percutaneouscoronaryintervention;Prognosis
目的 探讨急性冠状动脉综合征(ACS)伴高出血风险(HBR)患者经皮冠状动脉介入(PCI)治疗术后抗栓治疗及临床预后情况。方法 纳入2022年1月至2023年6月在首都医科大学附属北京安贞医院因ACS住院且行PCI治疗的患者18 382例。根据是否符合HBR学术研究联盟定义,将纳入患者分为HBR组和非HBR组。观察分析HBR对ACS患者PCI术后药物应用及院内结局的影响。结果 18 382例患者中判定为HBR的患者1 471例(HBR组),占8.0%。非HBR组患者16 911例。HBR组和非HBR组患者在入院时除口服抗凝药外其他药物使用比例均无明显差异。在出院用药中,HBR组患者有更高的比例接受氯吡格雷、口服抗凝药治疗[76.89%(1 131/1 471)比63.22%(10 691/16 911)、5.71%(84/1 471)比1.45%(246/16 911)],而接受替格瑞洛治疗的比例更低[16.38%(241/1 471)比28.45%(4 812/16 911)](组间比较SMD绝对值均>0.2)。HBR组患者住院时间长于非HBR组[4(2,5)d比3(2,4)d](组间比较SMD绝对值>0.2)。与非HBR组相比,HBR组在死亡、出血和再发心肌梗死事件上的发生比例较高,但SMD绝对值均未超过0.2,差异较小。结论 HBR可显著影响ACS患者PCI的药物应用,并导致不良预后。HBR患者应遵从现行指南管理,积极评估并个体化进行抗栓治疗以改善预后。
Objective To investigate the antithrombotic therapy and clinical prognosis of acute coronary syndrome (ACS) patients with high bleeding risk (HBR) after percutaneous coronary intervention (PCI). Methods A total of 18 382 ACS patients who underwent PCI in Beijing Anzhen Hospital, Capital Medical University from January 2022 to June 2023 were enrolled.The patients were divided into HBR group and non-HBR group according to whether they met the definition of HBR Academic Research Consortium. The effects of HBR on drug application and in-hospital outcomes in ACS patients after PCI were observed and analyzed. Results Among the 18 382 patients, there were 1 471 cases (accounting for 8.0%) diagnosed as HBR (HBR group) and 16 911 cases in the non-HBR group. There was no significant difference in the proportion of patients using other drugs except oral anticoagulants at admission between the HBR group and the non-HBR group.In the discharge medication, a higher proportion of patients in the HBR group received clopidogrel and oral anticoagulants[76.89%(1 131/1 471) vs 63.22%(10 691/16 911), 5.71%(84/1 471) vs 1.45%(246/16 911)], and a lower proportion received ticagrelor[16.38%(241/1 471) vs 28.45%(4 812/16 911)][the absolute values of standardized mean difference (SMD) between groups >0.2]. The hospitalization times of patients in the HBR group were longer than those in the non-HBR group [4(2,5)d vs 3(2,4)d](the absolute values of SMD between groups >0.2). Compared with the non-HBR group, the HBR group had a higher proportion of death, bleeding, and recurrent myocardial infarction events, but the absolute values of SMD did not exceed 0.2, which was a small difference. Conclusion HBR can significantly affect the drug application of PCI in ACS patients and lead to poor prognosis. HBR patients should be treated according to the current guidelines, actively evaluate and individualized antithrombotic therapy to improve the prognosis.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。